Company President at $DRI sells 85 shares in insider sale

Identified as $DRI’s President, Daniel J. Kiernan conducted a recent transaction on 07-29-2025, selling off 85 shares of the company for an approximate $17,332, as detailed in an updated SEC filing. This move accounted for roughly 26.0% of the shares of this specific stock class held by Kiernan, leaving them with a total of 242 shares of $DRI stock.

Over the past half-year, $DRI insiders engaged in 27 exchanges of the company’s stock on the open market, with all 27 transactions being sales and no purchases recorded during this period. Notable figures in the insider trading realm include President and CEO, Ricardo Cardenas, who executed 4 sales totaling 20,518 shares valued at an estimated $4,271,566. Similarly, SVP, Chief Supply Chain Officer Douglas J. Milanes made 3 sales, disposing of 19,840 shares equating to $4,199,789. Group President Melvin John Martin sold 17,303 shares in 4 sales, resulting in a total estimated at $3,733,370. Also noteworthy is Todd Burrowes, a Group President, who sold 13,569 shares amounting to $2,937,000.

Hedge fund activity surrounding $DRI revealed significant movements, with 491 institutional investors increasing their stakes in $DRI stock, while 404 decreased their positions in the last quarter. Some of the prominent changes included CITADEL ADVISORS LLC adding 1,294,559 shares to their portfolio in Q1 2025, amounting to $268,957,577, and GAMMA INVESTING LLC removing 923,504 shares in Q2 2025, totaling $201,296,166.

In the realm of congressional stock trading, members of Congress have engaged in one transaction involving $DRI stock within the last 6 months, with Representative Robert Bresnahan purchasing up to $15,000 intensities on 04/08.

On the analyst front, Wall Street issued buy ratings for $DRI stock in the recent past, with 14 firms providing positive outlooks on the stock. Notable reports included JP Morgan’s “Overweight” rating on 06/25/2025 and Raymond James’ “Outperform” rating on 06/23/2025.

Recent price targets gleaned from various analysts indicated a median target price of $237.5 set by 20 analysts over the last 6 months. Target prices included Andrew Strelzik from BMO Capital setting a target price of $215.0 on 06/25/2025 and John Ivankoe from JP Morgan setting a target price of $240.0 on 06/25/2025.